Display options
Cite
Pan JY, Zhang F, Sun CC, et al. miR-134: A Human Cancer Suppressor?. Mol Ther Nucleic Acids. 2016;6:140-149doi: 10.1016/j.omtn.2016.11.003.
Pan, J. Y., Zhang, F., Sun, C. C., Li, S. J., Li, G., Gong, F. Y., Bo, T., He, J., Hua, R. X., Hu, W. D., Yuan, Z. P., Wang, X., He, Q. Q., & Li, D. J. (2017). miR-134: A Human Cancer Suppressor?. Molecular therapy. Nucleic acids, 6140-149. https://doi.org/10.1016/j.omtn.2016.11.003
Pan, Jing-Yu, et al. "miR-134: A Human Cancer Suppressor?." Molecular therapy. Nucleic acids vol. 6 (2017): 140-149. doi: https://doi.org/10.1016/j.omtn.2016.11.003
Pan JY, Zhang F, Sun CC, Li SJ, Li G, Gong FY, Bo T, He J, Hua RX, Hu WD, Yuan ZP, Wang X, He QQ, Li DJ. miR-134: A Human Cancer Suppressor?. Mol Ther Nucleic Acids. 2017 Mar 17;6:140-149. doi: 10.1016/j.omtn.2016.11.003. Epub 2016 Dec 10. PMID: 28325280; PMCID: PMC5363400.
Copy Download .nbib Format: NLM
Share it on

Mol Ther Nucleic Acids. 2017 Mar 17;6:140-149. doi: 10.1016/j.omtn.2016.11.003. Epub 2016 Dec 10.

miR-134: A Human Cancer Suppressor?.

Molecular therapy. Nucleic acids

Jing-Yu Pan, Feng Zhang, Cheng-Cao Sun, Shu-Jun Li, Guang Li, Feng-Yun Gong, Tao Bo, Jing He, Rui-Xi Hua, Wei-Dong Hu, Zhan-Peng Yuan, Xin Wang, Qi-Qiang He, De-Jia Li

Affiliations

  1. Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China.
  2. Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China. Electronic address: [email protected].
  3. Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China; Wuhan Hospital for the Prevention and Treatment of Occupational Diseases, 430015 Wuhan, Hubei, P. R. China.
  4. Department of Oncology, Wuhan Pu-Ai Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430034 Wuhan, Hubei, P. R. China.
  5. Department of Infectious Diseases, Wuhan Medical Treatment Center, 430023 Wuhan, Hubei, P. R. China.
  6. Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 510623 Guangzhou, Guangdong, P. R. China.
  7. Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, 510080 Guangzhou, Guangdong, P. R. China.
  8. Department of Oncology, ZhongNan Hospital of Wuhan University, 430071 Wuhan, Hubei, P. R. China.
  9. Department of Toxicology, School of Public Health, Wuhan University, 430071 Wuhan, P. R. China.
  10. Department of Social Science and Public Health, School of Basic Medical Science, Jiujiang University, Jiujiang 332000, China.
  11. Department of Occupational and Environmental Health, School of Public Health, Wuhan University, 430071 Wuhan, Hubei, P. R. China. Electronic address: [email protected].

PMID: 28325280 PMCID: PMC5363400 DOI: 10.1016/j.omtn.2016.11.003

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs approximately 20-25 nt in length, which play crucial roles through directly binding to corresponding 3' UTR of targeted mRNAs. It has been reported that miRNAs are involved in numerous of diseases, including cancers. Recently, miR-134 has been identified to dysregulate in handles of human cancers, such as lung cancer, glioma, breast cancer, colorectal cancer, and so on. Increasing evidence indicates that miR-134 is essential for human carcinoma and participates in tumor cell proliferation, apoptosis, invasion and metastasis, drug resistance, as well as cancer diagnosis, treatment, and prognosis. Nevertheless, its roles in human cancer are still ambiguous, and its mechanisms are sophisticated as well, referring to a variety of targets and signal pathways, such as STAT5B, KRAS, MAPK/ERK signal pathway, Notch pathway, etc. Herein, we review the crucial roles of miR-134 in scores of human cancers via analyzing latest investigations, which might provide evidence for cancer diagnose, treatment, prognosis, or further investigations.

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: human cancer; miR-134; microRNA

References

  1. PLoS One. 2011;6(5):e20600 - PubMed
  2. Oncotarget. 2015 Sep 22;6(28):25533-74 - PubMed
  3. Biochem Biophys Res Commun. 2016 Feb 26;471(1):82-8 - PubMed
  4. Nature. 2007 Oct 11;449(7163):682-8 - PubMed
  5. Pharmacogenet Genomics. 2006 Jun;16(6):439-50 - PubMed
  6. Carcinogenesis. 2014 Jan;35(1):76-85 - PubMed
  7. FEBS Lett. 2012 Oct 19;586(20):3761-5 - PubMed
  8. J Exp Clin Cancer Res. 2013 Oct 16;32:76 - PubMed
  9. Mol Cancer. 2003 Jan 07;2:6 - PubMed
  10. Cell Death Differ. 2012 Nov;19(11):1733-40 - PubMed
  11. Science. 1992 Dec 4;258(5088):1650-4 - PubMed
  12. Cell Prolif. 2013 Jun;46(3):254-62 - PubMed
  13. J Pathol. 2007 Mar;211(4):463-70 - PubMed
  14. Cancer Res. 2003 Jan 1;63(1):1-5 - PubMed
  15. Int J Oncol. 2013 May;42(5):1533-40 - PubMed
  16. J Clin Neurosci. 2015 Mar;22(3):583-7 - PubMed
  17. Medicine (Baltimore). 2015 Apr;94(16):e767 - PubMed
  18. EMBO J. 2014 Oct 1;33(19):2231-46 - PubMed
  19. Mol Oncol. 2014 Feb;8(1):93-104 - PubMed
  20. Mol Biol Cell. 1995 Apr;6(4):387-400 - PubMed
  21. J Cell Sci. 2007 Oct 15;120(Pt 20):3688-99 - PubMed
  22. Oncotarget. 2016 Feb 16;7(7):8341-59 - PubMed
  23. Clin Cancer Res. 2000 Dec;6(12):4705-12 - PubMed
  24. J Cell Sci. 2012 Aug 1;125(Pt 15):3661-70 - PubMed
  25. Hepatology. 2013 Dec;58(6):1964-76 - PubMed
  26. Cancer Res Treat. 2014 Apr;46(2):178-85 - PubMed
  27. Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2526-31 - PubMed
  28. Int J Cancer. 2012 Sep 15;131(6):E884-96 - PubMed
  29. PLoS One. 2015 Mar 17;10(3):e0120337 - PubMed
  30. Hepatogastroenterology. 2015 May;62(139):615-9 - PubMed
  31. J Exp Med. 1998 Feb 16;187(4):587-600 - PubMed
  32. Lab Invest. 2004 Mar;84(3):320-31 - PubMed
  33. Asian Pac J Cancer Prev. 2015;16(8):3509-15 - PubMed
  34. PLoS One. 2014 Feb 03;9(2):e87665 - PubMed
  35. Sci Rep. 2016 Apr 20;6:24720 - PubMed
  36. Cancer Genomics Proteomics. 2013 May-Jun;10(3):93-113 - PubMed
  37. Mol Cell. 2011 Nov 18;44(4):517-31 - PubMed
  38. J Ethnopharmacol. 2016 Aug 22;190:74-82 - PubMed
  39. Int J Med Sci. 2015 Jul 16;12(7):590-8 - PubMed
  40. Genet Mol Res. 2015 Dec 14;14(4):16771-81 - PubMed
  41. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29 - PubMed
  42. Nat Genet. 2006 Jun;38 Suppl:S8-13 - PubMed
  43. Diabetes Metab Res Rev. 2009 Jan;25(1):41-9 - PubMed
  44. FEBS Lett. 2015 Jan 16;589(2):207-14 - PubMed
  45. J Cell Biol. 1999 Jan 25;144(2):281-92 - PubMed
  46. J Pathol. 2006 Apr;208(5):662-72 - PubMed
  47. Oncotarget. 2016 Apr 19;7(16):21510-26 - PubMed
  48. DNA Cell Biol. 2015 Jun;34(6):429-36 - PubMed
  49. Tumour Biol. 2015 Sep;36(9):6725-32 - PubMed
  50. Lung Cancer. 2012 Jul;77(1):16-23 - PubMed
  51. Mol Cancer. 2011 May 18;10:58 - PubMed
  52. Annu Rev Immunol. 1998;16:395-419 - PubMed
  53. J Exp Clin Cancer Res. 2011 Feb 17;30:20 - PubMed
  54. Lung Cancer. 2009 Feb;63(2):219-26 - PubMed
  55. Biol Reprod. 2014 Nov;91(5):116 - PubMed
  56. Nature. 2006 Jan 19;439(7074):283-9 - PubMed
  57. PLoS One. 2015 Apr 15;10(4):e0124007 - PubMed
  58. Oncotarget. 2015 Oct 6;6(30):30239-50 - PubMed
  59. Cell Oncol (Dordr). 2014 Oct;37(5):331-8 - PubMed
  60. PLoS One. 2008 Jun 18;3(6):e2436 - PubMed
  61. Genome Res. 2004 Sep;14(9):1741-8 - PubMed
  62. J Biol Chem. 2011 Sep 2;286(35):30706-13 - PubMed
  63. Ther Adv Respir Dis. 2011 Dec;5(6):409-18 - PubMed
  64. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  65. Oncotarget. 2015 Nov 24;6(37):39756-92 - PubMed
  66. Gene. 2016 Feb 15;577(2):221-6 - PubMed
  67. Cell Physiol Biochem. 2016;38(3):1015-29 - PubMed
  68. Clin Cancer Res. 2013 Jul 1;19(13):3600-10 - PubMed
  69. Tumour Biol. 2016 Aug;37(8):11485-93 - PubMed
  70. Int J Oncol. 2012 May;40(5):1553-60 - PubMed
  71. Annu Rev Biochem. 2010;79:351-79 - PubMed
  72. Nat Mater. 2014 Nov;13(11):1063-71 - PubMed
  73. Clin Cancer Res. 2014 Dec 1;20(23):5898-907 - PubMed
  74. Nat Rev Cancer. 2002 Jun;2(6):442-54 - PubMed
  75. Oncol Lett. 2015 Jun;9(6):2910-2916 - PubMed
  76. Cell Death Differ. 2014 May;21(5):720-34 - PubMed
  77. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  78. Oncotarget. 2015 Nov 17;6(36):38628-42 - PubMed
  79. BMC Genet. 2015 Sep 23;16:114 - PubMed
  80. Mol Cell. 2014 Jun 19;54(6):1042-1054 - PubMed
  81. In Vitro Cell Dev Biol Anim. 2012 Feb;48(2):131-6 - PubMed
  82. Mol Ther Nucleic Acids. 2014 Sep 23;3:e194 - PubMed
  83. Cell Res. 2008 Oct;18(10):997-1006 - PubMed
  84. Breast Cancer Res Treat. 2007 Mar;101(3):305-15 - PubMed
  85. J Clin Oncol. 2006 Apr 10;24(11):1770-83 - PubMed
  86. Cell Death Dis. 2016 Sep 29;7(9):e2384 - PubMed
  87. Trends Biochem Sci. 1997 Oct;22(10):388-93 - PubMed
  88. Mol Ther Nucleic Acids. 2015 Mar 10;4:e231 - PubMed
  89. Int J Clin Exp Pathol. 2015 Nov 01;8(11):14472-8 - PubMed
  90. Biotechnol Lett. 2015 Dec;37(12):2387-94 - PubMed
  91. Int J Cancer. 2014 Feb 15;134(4):811-21 - PubMed
  92. Oncotarget. 2016 Aug 9;7(32):51515-51524 - PubMed
  93. Front Mol Neurosci. 2013 Nov 12;6:37 - PubMed
  94. Biochem Biophys Res Commun. 2015 Aug 28;464(3):748-54 - PubMed
  95. Br J Cancer. 2012 Jun 19;107 Suppl 1:S85-91 - PubMed
  96. Mol Ther Nucleic Acids. 2015 Mar 17;4:e233 - PubMed
  97. Cell. 1993 Nov 19;75(4):805-16 - PubMed
  98. Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 - PubMed
  99. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  100. Oncotarget. 2015 Oct 27;6(33):34649-57 - PubMed
  101. J Pathol. 2010 Jan;220(1):71-86 - PubMed
  102. Cancer Res. 2012 Oct 1;72(19):4883-9 - PubMed
  103. PLoS One. 2016 Jan 26;11(1):e0146128 - PubMed
  104. J Cell Mol Med. 2016 Oct;20(10):1974-83 - PubMed
  105. Eur J Cancer. 2010 Jun;46(9):1692-702 - PubMed
  106. Oncotarget. 2016 Jun 14;7(24):35960-35978 - PubMed
  107. Nat Rev Cancer. 2006 Nov;6(11):857-66 - PubMed
  108. Sci Rep. 2013;3:1555 - PubMed
  109. Mol Cell. 2014 Sep 18;55(6):868-879 - PubMed
  110. Mol Cancer Ther. 2014 Feb;13(2):444-53 - PubMed
  111. Clin Cancer Res. 2008 May 1;14(9):2588-92 - PubMed

Publication Types